Arrowstreet Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arrowstreet Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-849,744	Closed	-$50.5M	–	1855
2025 Q4	$50.5M	Buy	849,744 +475,036	+127%	+$25.9M	0.03%	480
2025 Q3	$20.3M	Buy	374,708 +96,068	+34%	+$5.49M	0.01%	726
2025 Q2	$15.3M	Buy	278,640 +60,573	+28%	+$3.57M	0.01%	774
2025 Q1	$15.4M	Buy	+218,067	New	+$14.7M	0.01%	673
2019 Q2	–	Sell	-177,600	Closed	-$15.8M	–	1405
2019 Q1	$15.8M	Buy	+177,600	New	+$16.5M	0.04%	423
2016 Q1	–	Sell	-341,349	Closed	-$35.8M	–	1348
2015 Q4	$35.8M	Sell	341,349 -5,319	-2%	-$555K	0.16%	129
2015 Q3	$36.5M	Buy	346,668 +26,768	+8%	+$3.58M	0.17%	136
2015 Q2	$43.8M	Buy	+319,900	New	+$39.6M	0.25%	107
2013 Q4	–	Sell	-70,438	Closed	-$5.09M	–	1148
2013 Q3	$5.09M	Buy	+70,438	New	+$4.68M	0.03%	384

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's BMRN Position: Q1 2026 in Review

Arrowstreet Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 849,744 shares — an estimated $50.5M sold.

Arrowstreet Capital first reported a position in BMRN in Q3 2013 and held it in 9 quarters. The position peaked at $50.5M in Q4 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Arrowstreet Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Arrowstreet Capital sold 849,744 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $50.5M.
Arrowstreet Capital first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 9 quarters.
Arrowstreet Capital's BioMarin Pharmaceuticals position peaked at $50.5M in Q4 2025.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.